Definium Therapeutics is trading 5% lower at $34.43, with possible biotech-sector weakness the leading explanation for the October 6 move. - No clear company-specific announcement explaining the move surfaced in the search; listed press releases cover earlier developments, including September Phase 3 results. - Search results do not independently confirm a biotech-sector decline. Broader U.S. indexes are reported higher, making a broad-market selloff unsupported; available evidence favors sector context with limited confidence.